drugset

drugset / Trial / NCT04342676

Lymph Node Ratio and Kras Mutation in R Colon Cancer

NCT04342676 ↗

Phase 3 Completed 433 enrolled Mansoura University

NaSingle-groupOpen-labelBasic science

Summary

clinical impact of LN ratio with Kras expression in colon cancer

Timeline

Start: 2017-03-10
Primary completion: 2019-08-25
Completion: 2019-08-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Panitumumab	Monoclonal antibody	—	—

Indications